# 60 Degrees Pharmaceuticals, Inc.: financial statements, quarterly

SXTP · Nasdaq · CIK 1946563 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sxtp.md) · [Financials](/companies/sxtp/financials.md) · [Filings](/companies/sxtp/filings.md) · [Insiders](/companies/sxtp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sxtp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [51.2](/filings/0001213900-24-098195.md) | [126 d](/filings/0001013762-25-003343.md) | [106](/filings/0001213900-25-043779.md) | [125](/filings/0001554855-25-001009.md) | [135](/filings/0001554855-25-002032.md) | [242 d](/filings/0001554855-26-000467.md) | [164](/filings/0001554855-26-001058.md) | [101](/filings/0001554855-26-001860.md) | [438](/filings/0001554855-25-002032.md) | [303 d](/filings/0001554855-26-000467.md) | [162](/filings/0001554855-26-001058.md) | [208](/filings/0001554855-26-001860.md) |
| Cost of revenue | $k | [71.2](/filings/0001213900-24-098195.md) | [146 d](/filings/0001013762-25-003343.md) | [65.4](/filings/0001213900-25-043779.md) | [89.6](/filings/0001554855-25-001009.md) | [112](/filings/0001554855-25-002032.md) | [118 d](/filings/0001554855-26-000467.md) | [73.3](/filings/0001554855-26-001058.md) | [50.1](/filings/0001554855-26-001860.md) | [538](/filings/0001554855-25-002032.md) | [121 d](/filings/0001554855-26-000467.md) | [85.7](/filings/0001554855-26-001058.md) | [151](/filings/0001554855-26-001860.md) |
| Gross profit | $k | [(20.0)](/filings/0001213900-24-098195.md) | [(20.6) d](/filings/0001013762-25-003343.md) | [40.2](/filings/0001213900-25-043779.md) | [35.4](/filings/0001554855-25-001009.md) | [23.6](/filings/0001554855-25-002032.md) | [124 d](/filings/0001554855-26-000467.md) | [90.3](/filings/0001554855-26-001058.md) | [50.9](/filings/0001554855-26-001860.md) | [(100)](/filings/0001554855-25-002032.md) | [183 d](/filings/0001554855-26-000467.md) | [76.4](/filings/0001554855-26-001058.md) | [56.8](/filings/0001554855-26-001860.md) |
| Research and development | $k | [264](/filings/0001213900-24-098195.md) | [100 d](/filings/0001013762-25-003343.md) | [337](/filings/0001213900-25-043779.md) | [3,095](/filings/0001554855-25-001009.md) | [940](/filings/0001554855-25-002032.md) | [614 d](/filings/0001554855-26-000467.md) | [371](/filings/0001554855-26-001058.md) | [232](/filings/0001554855-26-001860.md) | [810](/filings/0001554855-25-002032.md) | [639 d](/filings/0001554855-26-000467.md) | [281](/filings/0001554855-26-001058.md) | [599](/filings/0001554855-26-001860.md) |
| Operating income | $k | [(1,522)](/filings/0001213900-24-098195.md) | [(1,894) d](/filings/0001013762-25-003343.md) | [(1,342)](/filings/0001213900-25-043779.md) | [(4,189)](/filings/0001554855-25-001009.md) | [(2,119)](/filings/0001554855-25-002032.md) | [(2,065) d](/filings/0001554855-26-000467.md) | [(1,911)](/filings/0001554855-26-001058.md) | [(1,606)](/filings/0001554855-26-001860.md) | [(2,326)](/filings/0001554855-25-002032.md) | [(1,917) d](/filings/0001554855-26-000467.md) | [(2,095)](/filings/0001554855-26-001058.md) | [(2,271)](/filings/0001554855-26-001860.md) |
| Interest expense | $k | [40.1](/filings/0001213900-23-088610.md) | [5.4 d](/filings/0001213900-24-028577.md) | [1.4](/filings/0001213900-24-043323.md) | [3.6](/filings/0001554855-25-001009.md) | [1.5](/filings/0001554855-25-002032.md) | [1.4 d](/filings/0001554855-26-000467.md) | [1.8](/filings/0001554855-26-001058.md) | [1.2](/filings/0001554855-26-001860.md) | [1.7](/filings/0001554855-25-002032.md) | [3.1 d](/filings/0001554855-26-000467.md) | [1.4](/filings/0001554855-26-001058.md) | [1.4](/filings/0001554855-26-001860.md) |
| Income tax | $k | [0.1](/filings/0001213900-24-098195.md) | [0.1 d](/filings/0001013762-25-003343.md) | [0.1](/filings/0001213900-25-043779.md) | [0.4](/filings/0001554855-25-001009.md) | [0.3](/filings/0001554855-25-002032.md) | [(0.8) d](/filings/0001554855-26-000467.md) | [0.1](/filings/0001213900-25-043779.md) | [1.5](/filings/0001554855-25-001009.md) | [0.3](/filings/0001554855-25-002032.md) | [(1.8) d](/filings/0001554855-26-000467.md) | not reported | not reported |
| Net income | $k | [4,183](/filings/0001213900-24-098195.md) | [(2,012) d](/filings/0001013762-25-003343.md) | [430](/filings/0001213900-25-043779.md) | [(4,173)](/filings/0001554855-25-001009.md) | [(2,160)](/filings/0001554855-25-002032.md) | [(2,045) d](/filings/0001554855-26-000467.md) | [(1,877)](/filings/0001554855-26-001058.md) | [(1,734)](/filings/0001554855-26-001860.md) | [(2,316)](/filings/0001554855-25-002032.md) | [(1,439) d](/filings/0001554855-26-000467.md) | [(2,089)](/filings/0001554855-26-001058.md) | [(2,265)](/filings/0001554855-26-001860.md) |
| Diluted EPS | $ per share | [9.13](/filings/0001213900-24-098195.md) | not reported | [1.83](/filings/0001213900-25-043779.md) | [(21.12)](/filings/0001554855-25-001009.md) | [(2.92)](/filings/0001554855-25-002032.md) | not reported | [(6.25)](/filings/0001554855-26-001058.md) | [(5.01)](/filings/0001554855-26-001860.md) | [(0.66)](/filings/0001554855-25-002032.md) | not reported | [(1.28)](/filings/0001554855-26-001058.md) | [(0.90)](/filings/0001554855-26-001860.md) |
| Basic EPS | $ per share | [9.13](/filings/0001213900-24-098195.md) | not reported | [1.83](/filings/0001213900-25-043779.md) | [(21.12)](/filings/0001554855-25-001009.md) | [(4.65)](/filings/0001554855-25-002032.md) | not reported | [(6.25)](/filings/0001554855-26-001058.md) | [(5.01)](/filings/0001554855-26-001860.md) | [(0.66)](/filings/0001554855-25-002032.md) | not reported | [(1.28)](/filings/0001554855-26-001058.md) | [(0.90)](/filings/0001554855-26-001860.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [2,219](/filings/0001213900-23-088610.md) | [2,142](/filings/0001013762-25-003343.md) | [2,895](/filings/0001213900-24-043323.md) | [1,577](/filings/0001213900-24-068673.md) | [3,301](/filings/0001213900-24-098195.md) | [1,659](/filings/0001554855-26-000467.md) | [3,452](/filings/0001213900-25-043779.md) | [1,967](/filings/0001554855-25-001009.md) | [4,116](/filings/0001554855-25-002032.md) | [1,510](/filings/0001554855-26-001860.md) | [3,338](/filings/0001554855-26-001058.md) | [1,023](/filings/0001554855-26-001860.md) |
| Current assets | $k | [8,895](/filings/0001213900-23-088610.md) | [7,243](/filings/0001013762-25-003343.md) | [7,906](/filings/0001213900-24-043323.md) | [3,763](/filings/0001213900-24-068673.md) | [6,891](/filings/0001213900-24-098195.md) | [5,386](/filings/0001554855-26-000467.md) | [5,650](/filings/0001213900-25-043779.md) | [3,844](/filings/0001554855-25-001009.md) | [6,309](/filings/0001554855-25-002032.md) | [4,895](/filings/0001554855-26-001860.md) | [6,260](/filings/0001554855-26-001058.md) | [3,731](/filings/0001554855-26-001860.md) |
| Total assets | $k | [9,150](/filings/0001213900-23-088610.md) | [7,784](/filings/0001013762-25-003343.md) | [8,379](/filings/0001213900-24-043323.md) | [4,327](/filings/0001213900-24-068673.md) | [7,421](/filings/0001213900-24-098195.md) | [5,759](/filings/0001554855-26-000467.md) | [5,978](/filings/0001213900-25-043779.md) | [4,182](/filings/0001554855-25-001009.md) | [6,689](/filings/0001554855-25-002032.md) | [5,366](/filings/0001554855-26-001860.md) | [6,763](/filings/0001554855-26-001058.md) | [4,283](/filings/0001554855-26-001860.md) |
| Current liabilities | $k | [2,481](/filings/0001213900-23-088610.md) | [2,835](/filings/0001013762-25-003343.md) | [1,104](/filings/0001213900-24-043323.md) | [1,219](/filings/0001213900-24-068673.md) | [1,310](/filings/0001213900-24-098195.md) | [1,657](/filings/0001554855-26-000467.md) | [1,802](/filings/0001213900-25-043779.md) | [1,691](/filings/0001554855-25-001009.md) | [2,197](/filings/0001554855-25-002032.md) | [1,843](/filings/0001554855-26-001860.md) | [1,876](/filings/0001554855-26-001058.md) | [1,605](/filings/0001554855-26-001860.md) |
| Total liabilities | $k | [2,634](/filings/0001213900-23-088610.md) | [2,986](/filings/0001013762-25-003343.md) | [1,254](/filings/0001213900-24-043323.md) | [1,368](/filings/0001213900-24-068673.md) | [1,458](/filings/0001213900-24-098195.md) | [1,804](/filings/0001554855-26-000467.md) | [1,949](/filings/0001213900-25-043779.md) | [1,836](/filings/0001554855-25-001009.md) | [2,342](/filings/0001554855-25-002032.md) | [1,987](/filings/0001554855-26-001860.md) | [2,019](/filings/0001554855-26-001058.md) | [1,754](/filings/0001554855-26-001860.md) |
| Long-term debt | $k | [150](/filings/0001213900-23-088610.md) | [150](/filings/0001213900-24-028577.md) | [150](/filings/0001213900-24-043323.md) | [150](/filings/0001213900-24-068673.md) | [150](/filings/0001213900-24-098195.md) | [147](/filings/0001554855-26-000467.md) | [150](/filings/0001213900-25-043779.md) | [150](/filings/0001554855-25-001009.md) | [150](/filings/0001554855-25-002032.md) | [144](/filings/0001554855-26-000467.md) | [150](/filings/0001554855-26-001058.md) | [150](/filings/0001554855-26-001860.md) |
| Current portion of debt | $k | not reported | [8.8](/filings/0001013762-25-003343.md) | [8.8](/filings/0001213900-24-043323.md) | [8.8](/filings/0001213900-24-068673.md) | [8.8](/filings/0001213900-24-098195.md) | [8.8](/filings/0001554855-26-000467.md) | [8.8](/filings/0001213900-25-043779.md) | [8.8](/filings/0001554855-25-001009.md) | [8.8](/filings/0001554855-25-002032.md) | [8.8](/filings/0001554855-26-001860.md) | [8.8](/filings/0001554855-26-001058.md) | [2.0](/filings/0001554855-26-001860.md) |
| Short-term borrowings | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $k | [6,516](/filings/0001213900-24-098195.md) | [4,870](/filings/0001013762-25-003343.md) | [7,200](/filings/0001213900-24-043323.md) | [3,035](/filings/0001213900-24-068673.md) | [6,040](/filings/0001213900-24-098195.md) | [4,036](/filings/0001554855-26-000467.md) | [4,110](/filings/0001213900-25-043779.md) | [2,428](/filings/0001554855-25-001009.md) | [4,430](/filings/0001554855-25-002032.md) | [3,463](/filings/0001554855-26-001860.md) | [4,829](/filings/0001554855-26-001058.md) | [2,614](/filings/0001554855-26-001860.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,753) d](/filings/0001213900-24-098195.md) | [(63.7) d](/filings/0001013762-25-003343.md) | [(1,140)](/filings/0001213900-25-043779.md) | [(1,188) d](/filings/0001554855-25-001009.md) | [(1,681) d](/filings/0001554855-25-002032.md) | [(1,638) d](/filings/0001554855-26-000467.md) | [(1,597)](/filings/0001554855-26-001058.md) | [(1,450) d](/filings/0001554855-26-001860.md) | [(2,109) d](/filings/0001554855-25-002032.md) | [(1,692) d](/filings/0001554855-26-000467.md) | [(2,742)](/filings/0001554855-26-001058.md) | [(2,232) d](/filings/0001554855-26-001860.md) |
| Capital expenditure | $k | not reported | [55.8 d](/filings/0001013762-25-003343.md) | not reported | not reported | [13.8 d](/filings/0001554855-25-002032.md) | [0.0 d](/filings/0001554855-26-000467.md) | [2.7](/filings/0001554855-26-001058.md) | [47.3 d](/filings/0001554855-26-001860.md) | [10.0 d](/filings/0001554855-25-002032.md) | [79.9 d](/filings/0001554855-26-000467.md) | [30.0](/filings/0001554855-26-001058.md) | [0.0 d](/filings/0001554855-26-001860.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-09-30) | period not labelled (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [2,386](/filings/0001213900-23-088610.md) | [2,304](/filings/0001213900-24-043323.md) | [198](/filings/0001213900-24-068673.md) | [448](/filings/0001213900-24-098195.md) | [169](/filings/0001213900-25-043779.md) | [203](/filings/0001554855-25-001009.md) | [2,153](/filings/0001554855-25-002032.md) | [321](/filings/0001554855-26-001058.md) | [368](/filings/0001554855-26-001860.md) | [3,675](/filings/0001554855-25-002032.md) | [1,726](/filings/0001554855-26-001058.md) | [2,654](/filings/0001554855-26-001860.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,516,988 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001554855-26-001860.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.